These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11899380)

  • 21. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Narod S
    J Natl Cancer Inst; 1999 Jan; 91(2):188. PubMed ID: 9923863
    [No Abstract]   [Full Text] [Related]  

  • 23. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.
    Powles TJ; Jones AL; Ashley SE; O'Brien ME; Tidy VA; Treleavan J; Cosgrove D; Nash AG; Sacks N; Baum M
    Breast Cancer Res Treat; 1994; 31(1):73-82. PubMed ID: 7981459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemoprevention of breast cancer - with special interest of tamoxifen].
    Nagykálnai T
    Magy Onkol; 2001; 45(5):377-383. PubMed ID: 12050683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemopreventive effect of tamoxifen on familial breast cancer].
    Funahashi H
    Nihon Rinsho; 2000 Jun; 58(6):1267-71. PubMed ID: 10879052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of tamoxifen use: An update for the surgical oncologist.
    Heerdt AS; Borgen PI
    J Surg Oncol; 1999 Sep; 72(1):42-9. PubMed ID: 10477879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of the main outcomes in breast-cancer prevention trials.
    Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
    Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
    Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Italian study on the chemoprevention of breast cancer with tamoxifen].
    Veronesi U; Costa A; Sacchini V; Luini A; Bonanni B; Veronesi P; Rotmensz N; Boyle P
    Contracept Fertil Sex; 1995 Apr; 23(4):258-60. PubMed ID: 7757133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.
    Fallowfield L; Fleissig A; Edwards R; West A; Powles TJ; Howell A; Cuzick J
    J Clin Oncol; 2001 Apr; 19(7):1885-92. PubMed ID: 11283119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention of breast cancer: a model for change.
    Jordan VC; Morrow M
    J Clin Oncol; 2002 Jan; 20(1):1-3. PubMed ID: 11773145
    [No Abstract]   [Full Text] [Related]  

  • 38. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.